

# Jacek Jassem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6642668/publications.pdf>

Version: 2024-02-01

267  
papers

29,090  
citations

25014

57  
h-index

5249

165  
g-index

272  
all docs

272  
docs citations

272  
times ranked

32758  
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. <i>Cancer Treatment Reviews</i> , 2022, 104, 102359.	3.4	9
2	Lung cancer in Europe: The way forward. <i>Tobacco Prevention and Cessation</i> , 2022, 8, 1-2.	0.2	1
3	Impact of Tobacco Smoking on Outcomes of Radiotherapy: A Narrative Review. <i>Current Oncology</i> , 2022, 29, 2284-2300.	0.9	5
4	Complementary and Alternative Therapies in Oncology. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5071.	1.2	6
5	Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i> -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3593-3602.	0.8	43
6	Abstract LB168: Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study. <i>Cancer Research</i> , 2022, 82, LB168-LB168.	0.4	1
7	Phase 3 trial of lorlatinib in treatment-naïve patients (Pts) with <i>ALK</i> -positive advanced non-small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9070-9070.	0.8	5
8	First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9026-LBA9026.	0.8	12
9	New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary. <i>Cancers</i> , 2022, 14, 3429.	1.7	5
10	ALK alterations in salivary gland carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 933-941.	1.4	9
11	A View from the past into our collective future: the oncofertility consortium vision statement. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 3-15.	1.2	25
12	Comparison of claudin-3 and claudin-4 expression in bilateral and unilateral breast cancer. <i>Neoplasma</i> , 2021, 68, 283-289.	0.7	2
13	Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review). <i>Translational Lung Cancer Research</i> , 2021, 10, 2018-2031.	1.3	9
14	Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents. <i>Translational Lung Cancer Research</i> , 2021, 10, 2032-2047.	1.3	12
15	Radiotherapy in thoracic malignancies: the preface. <i>Translational Lung Cancer Research</i> , 2021, 10, 1928-1929.	1.3	0
16	Molecular Profiles of Brain Metastases: A Focus on Heterogeneity. <i>Cancers</i> , 2021, 13, 2645.	1.7	16
17	The European Code of Cancer Practice. <i>Journal of Cancer Policy</i> , 2021, 28, 100282.	0.6	22
18	imPlatelet classifier: image-converted RNA biomarker profiles enable blood-based cancer diagnostics. <i>Molecular Oncology</i> , 2021, 15, 2688-2701.	2.1	16

#	ARTICLE	IF	CITATIONS
19	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naïve Programmed Death-Ligand 1 "Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	0.5	85
20	A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 676732.	1.3	14
21	Transcriptomic landscape of blood platelets in healthy donors. <i>Scientific Reports</i> , 2021, 11, 15679.	1.6	22
22	Authors'™ Reply to Role of Primary Prevention in Lung Cancer Control in Poland. <i>Journal of Thoracic Oncology</i> , 2021, 16, e94-e95.	0.5	0
23	Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10934.	1.8	7
24	Prognostic Significance of Wnt1, Wnt2, E-Cadherin, and $\beta$ -catenin Expression in Operable Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 711-722.	1.3	1
25	Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review. <i>Cancers</i> , 2021, 13, 5306.	1.7	0
26	Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , 2021, 13, 5731.	1.7	13
27	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	1.3	14
28	The scope of complementary and alternative medicine in Poland. <i>Nowotwory</i> , 2021, 71, 357-372.	0.1	2
29	Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. <i>Oncologist</i> , 2020, 25, e598-e601.	1.9	18
30	Lung Cancer in Poland. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1271-1276.	0.5	16
31	O81 "IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1 "selected NSCLC. , 2020, , .		6
32	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. <i>European Journal of Cancer</i> , 2020, 127, 160-172.	1.3	112
33	Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 528-529.	5.2	4
34	IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21623-e21623.	0.8	12
35	Multidisciplinary team care in advanced lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1690-1698.	1.3	20
36	Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits. <i>Journal of Clinical Medicine</i> , 2020, 9, 1532.	1.0	50

#	ARTICLE	IF	CITATIONS
37	Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.. Journal of Clinical Oncology, 2020, 38, 9594-9594.	0.8	4
38	Changing paradigms in breast cancer treatment. European Journal of Translational and Clinical Medicine, 2020, 3, 53-63.	0.0	2
39	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 1619-1627.	0.5	11
40	Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. Lancet Oncology, The, 2019, 20, 1482-1485.	5.1	2
41	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 2019, 120, 132-139.	1.3	24
42	Lung cancer: a preventable disease. Translational Lung Cancer Research, 2019, 8, S1-S2.	1.3	2
43	Tobacco smoking after diagnosis of cancer: clinical aspects. Translational Lung Cancer Research, 2019, 8, S50-S58.	1.3	85
44	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptorâ€“Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of Clinical Oncology, 2019, 37, 105-114.	0.8	72
45	Folate/homocysteine metabolism and lung cancer risk among smokers. PLoS ONE, 2019, 14, e0214462.	1.1	18
46	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	6.3	2,347
47	Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. Oncologist, 2019, 24, e30-e37.	1.9	19
48	Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach. Translational Lung Cancer Research, 2019, 8, S387-S390.	1.3	4
49	Indeed, Nuance Matters. Journal of Thoracic Oncology, 2019, 14, e16-e17.	0.5	0
50	Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.. Journal of Clinical Oncology, 2019, 37, 234-234.	0.8	4
51	Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses?. Advances in Intelligent Systems and Computing, 2019, , 123-130.	0.5	0
52	Prognostic value of broad-spectrum keratin clones AE1/AE3 and CAM5.2 in small cell lung cancer patients undergoing pulmonary resection. Acta Biochimica Polonica, 2019, 66, 111-114.	0.3	5
53	Genomic characterization of brain metastases (BM) in high-grade serous ovarian cancer (HGSOC).. Journal of Clinical Oncology, 2019, 37, e13580-e13580.	0.8	0
54	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treatment Reviews, 2018, 66, 114-121.	3.4	28

#	ARTICLE	IF	CITATIONS
55	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. <i>Lung Cancer</i> , 2018, 118, 111-118.	0.9	38
56	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
57	Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. <i>BMC Cancer</i> , 2018, 18, 295.	1.1	23
58	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2018, 391, 1163-1173.	6.3	3,542
59	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
60	Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. <i>European Journal of Cancer</i> , 2018, 104, 127-136.	1.3	23
61	Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 71, 59-67.	3.4	39
62	“Teachable Moment” Interventions in Lung Cancer: Why Action Matters. <i>Journal of Thoracic Oncology</i> , 2018, 13, 603-605.	0.5	16
63	Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 71-77.	3.4	64
64	Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. <i>Nature Communications</i> , 2018, 9, 2705.	5.8	91
65	NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 799-811.	5.1	56
66	Erlotinib as adjuvant therapy in EGFR-mutant NSCLC. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 808-810.	5.2	1
67	Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 327-338.	1.1	37
68	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 975-986.	5.1	296
69	Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5003-5003.	0.8	4
70	Systemic therapy for cervical carcinoma – current status. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2018, 30, 209-221.	0.7	29
71	Pharmacotherapy of pain in cancer patients – recommendations of the Polish Association for the Study of Pain, Polish Society of Palliative Medicine, Polish Society of Oncology, Polish Society of Family Medicine, Polish Society of Anaesthesiology and Intensive Therapy and Association of Polish Surgeons. <i>Polski Przegląd Chirurgiczny</i> , 2018, 90, 51-80.	0.2	9
72	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis focused on cell cycle regulation. <i>Histology and Histopathology</i> , 2018, 33, 55-64.	0.5	1

#	ARTICLE	IF	CITATIONS
73	Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. <i>Oncologist</i> , 2017, 22, 375-e30.	1.9	25
74	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. <i>Targeted Oncology</i> , 2017, 12, 97-109.	1.7	56
75	Serum lipid profile discriminates patients with early lung cancer from healthy controls. <i>Lung Cancer</i> , 2017, 112, 69-74.	0.9	57
76	Post-mastectomy radiation therapy after breast reconstruction: Indications, timing and results. <i>Breast</i> , 2017, 34, S95-S98.	0.9	10
77	Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, e65-e75.	1.1	14
78	A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). <i>Clinical Colorectal Cancer</i> , 2017, 16, 103-114.e3.	1.0	22
79	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
80	Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation. <i>Oncology Letters</i> , 2017, 15, 1912-1916.	0.8	11
81	Dual HER2 Blockade. <i>Breast Care</i> , 2017, 12, 345-349.	0.8	1
82	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	0.8	251
83	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.	0.8	311
84	Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2514.	0.8	22
85	Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study. <i>Acta Biochimica Polonica</i> , 2017, 64, 513-518.	0.3	25
86	Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4001-4001.	0.8	65
87	An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. <i>Oncotarget</i> , 2017, 8, 17270-17278.	0.8	3
88	Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab. <i>Oncotarget</i> , 2017, 8, 104149-104159.	0.8	8
89	Review of Polish and international guidelines on hormonal therapy in localized prostate cancer. <i>Nowotwory</i> , 2017, 66, 403-407.	0.1	0
90	Prognostic value of NK and T-lymphocytes markers in operable non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11556-11556.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Castleman's disease mimicking lymph node metastases in a young woman with laryngeal cancer. <i>Wspolczesna Onkologia</i> , 2016, 5, 421-424.	0.7	0
92	Pulsed-dose-rate peri-operative brachytherapy as an interstitial boost in organ-sparing treatment of breast cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 492-496.	0.4	1
93	Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab. , 2016, , 225-236.		0
94	Serum mass profile signature as a biomarker of early lung cancer. <i>Lung Cancer</i> , 2016, 99, 46-52.	0.9	25
95	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11
96	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. <i>ESMO Open</i> , 2016, 1, e000004.	2.0	12
97	Highlights from the San Antonio Breast Cancer Symposium 2015. <i>ESMO Open</i> , 2016, 1, e000043.	2.0	1
98	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. <i>ESMO Open</i> , 2016, 1, e000142.	2.0	95
99	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1273-1281.	0.5	71
100	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. <i>Breast Cancer Research</i> , 2016, 18, 43.	2.2	90
101	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 822-835.	5.1	390
102	Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 194-199.	3.4	9
103	Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 765-773.	1.7	52
104	Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. <i>Oncologist</i> , 2016, 21, 1183-1190.	1.9	37
105	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
106	A comparison between DASL and Affymetrix on probing the whole-transcriptome. <i>Journal of the Korean Statistical Society</i> , 2016, 45, 149-155.	0.3	1
107	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	5.1	125
108	Alectinib in crizotinib-resistant, ALK-positive NSCLC. <i>Lancet Oncology</i> , The, 2016, 17, 134-135.	5.1	2



#	ARTICLE	IF	CITATIONS
109	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	0.6	122
110	Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5006-5006.	0.8	40
111	Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. <i>Oncotarget</i> , 2016, 7, 550-564.	0.8	6
112	Systemic therapy for endometrial stromal sarcomas: current treatment options. <i>Ginekologia Polska</i> , 2016, 87, 594-597.	0.3	7
113	Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20580-e20580.	0.8	0
114	Bright and dark sides of evidence-based medicine. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 347-52.	0.3	0
115	Assessment of health related quality of life (QOL) in phase III trials in advanced colorectal cancer (CRC): Frequency, time trends, and QOL improvement.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18209-e18209.	0.8	0
116	Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1076-1076.	0.8	0
117	Chemotherapy for advanced colorectal patients: daily practice results may not reflect the outcomes of prospective clinical trials. <i>Nowotwory</i> , 2016, 66, 285-292.	0.1	0
118	Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1083-1090.	0.5	30
119	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. <i>BMC Genomics</i> , 2015, 16, 752.	1.2	12
120	Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 1241-9.	0.6	24
121	Pulsed-dose-rate post-operative vaginal cuff brachytherapy for endometrial cancer: preliminary report. <i>Journal of Contemporary Brachytherapy</i> , 2015, 1, 72-75.	0.4	0
122	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482.	5.1	762
123	Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1067-1075.	0.5	15
124	Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 8-15.	1.1	47
125	Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. <i>Journal of Neuro-Oncology</i> , 2015, 122, 205-216.	1.4	31
126	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 109-117.	0.6	15



#	ARTICLE	IF	CITATIONS
127	Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients. Pathology and Oncology Research, 2015, 21, 1229-1236.	0.9	4
128	Caring for relatives with lung cancer in Europe: an evaluation of caregiversâ€™ experience. Quality of Life Research, 2015, 24, 2843-2852.	1.5	28
129	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast, 2015, 24, 182-190.	0.9	44
130	The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 61-68.	1.2	32
131	Tailoring therapiesâ€”improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546.	0.6	1,449
132	Public Perception of Cancer Care in Poland and Austria. Oncologist, 2015, 20, 28-36.	1.9	7
133	A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Science Translational Medicine, 2015, 7, 302ra136.	5.8	436
134	Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2015, 33, 7501-7501.	0.8	6
135	SkutecznoÅ›ć i koszty leczenia raka odbytnicy w Polsce; podejÅ›cie regionalne. Nowotwory, 2015, 65, 271-280.	0.1	1
136	Systemowe uwarunkowania opÅ›ieÅ›nieÅ›, w diagnostyce i leczeniu kobiet chorych na raka piersi w Polsce. Nowotwory, 2015, 64, 483-490.	0.1	0
137	Czy radioterapia u chorych na raka piersi po operacji oszczÅ›dzajÅ›cej moÅ›ze byÅ› jeszcze krÅ›tsza, niÅ› obecnie zalecana?. Nowotwory, 2015, 64, 542-543.	0.1	0
138	RÅ›wnoczesne przerzuty raka nerki do trzustki i tarczycy â€” opis przypadku i przeglÅ›d piÅ›miennictwa. Nowotwory, 2015, 65, 48-50.	0.1	1
139	Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 4506-4506.	0.8	7
140	MicroRNA (MiRNA) expression profiles in early colon cancer (CC) and lung adenocarcinoma (AC).. Journal of Clinical Oncology, 2015, 33, e22062-e22062.	0.8	0
141	Immune response in breast cancer brain metastases (BM) and their microenvironment.. Journal of Clinical Oncology, 2015, 33, e22112-e22112.	0.8	0
142	A Catalyst for Change: The European Cancer Patient's Bill of Rights. Oncologist, 2014, 19, 217-224.	1.9	35
143	Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Nonâ€”Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 2059-2066.	0.8	127
144	Delays in diagnosis and treatment of breast cancer: a multinational analysis. European Journal of Public Health, 2014, 24, 761-767.	0.1	98

#	ARTICLE	IF	CITATIONS
145	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. <i>Clinical Cancer Research</i> , 2014, 20, 3299-3309.	3.2	141
146	E-Cigarettes and Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 438-441.	0.5	46
147	Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff. <i>Clinical Cancer Research</i> , 2014, 20, 2805-2813.	3.2	28
148	Are bilateral breast cancers and breast cancers coexisting with ovarian cancer different from solitary tumors? A pair-matched immunohistochemical analysis aimed at intrinsic tumor phenotype. <i>Pathology International</i> , 2014, 64, 508-517.	0.6	3
149	DNA Double-Strand Break Repair Genes and Oxidative Damage in Brain Metastasis of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	57
150	Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner. <i>Clinical Cancer Research</i> , 2014, 20, 2727-2739.	3.2	57
151	Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01). <i>Clinical Lung Cancer</i> , 2014, 15, 258-265.	1.1	19
152	Zalecenia metodyczne dotyczÄ...ce oceny mutacji genu EGFR oraz rearanÅ¼acji genu ALK w kwalifikacji chorych na niedrobnokomÅ³rkowego raka pÅ¼ca do terapii ukierunkowanych molekularnie. <i>Pneumonologia I Alergologia Polska</i> , 2014, 82, 437-444.	0.6	2
153	Miliary Brain Metastases in a Patient with ROS1-Rearranged Lung Adenocarcinoma: A Case Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, e34-e36.	0.5	17
154	Tobacco control in Poland-successes and challenges. <i>Translational Lung Cancer Research</i> , 2014, 3, 280-5.	1.3	27
155	SkutecznoÅ i koszty leczenia raka piersi w Polsce; podejÅcie regionalne. <i>Nowotwory</i> , 2014, 64, 24-32.	0.1	3
156	Åywnienie drogÄ... przewodu pokarmowego (Å¼ywnienie dojelitowe). <i>Nowotwory</i> , 2014, 64, 436-442.	0.1	1
157	Rola systemowych metod leczenia u chorych na niedrobnokomÅ³rkowego raka pÅ¼ca i zÅoÅliwego miÅdzybÅoniaka opÅ¼ucnej: uaktualnione zalecenia ekspertÅ³w. <i>Nowotwory</i> , 2014, 64, 61-75.	0.1	0
158	Rokownicze znaczenie wzglÅdnej intensywnoÅci dawki oraz wartoÅci parametrÅ³w morfologii krwi w trakcie pooperacyjnej chemioterapii chorych na raka piersi. <i>Nowotwory</i> , 2014, 64, 135-142.	0.1	0
159	Niesteroidowe leki przeciwzapalne w profilaktyce i leczeniu nowotworÅ³w jelita grubego. <i>Nowotwory</i> , 2014, 64, 175-179.	0.1	1
160	Public perception of cancer care in Poland and Austria: A survey study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17559-e17559.	0.8	0
161	Immunohistochemical (IHC) prediction of lapatinib efficacy in HER2-positive advanced breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 639-639.	0.8	0
162	Zalecenia metodyczne dotyczÄ...ce oceny mutacji genu EGFR oraz rearanÅ¼acji genu ALK w kwalifikacji chorych na niedrobnokomÅ³rkowego raka pÅ¼ca do terapii ukierunkowanych molekularnie. <i>Nowotwory</i> , 2014, 64, 336-342.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Badania kontrolne po leczeniu w najczÄ™stszych nowotworach litych u dorosÅ„ych. Nowotwory, 2014, 64, 415-435.	0.1	1
164	Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. International Journal of Clinical and Experimental Pathology, 2014, 7, 353-63.	0.5	9
165	Main Histologic Types of Non-“Small-Cell Lung-“Cancer Differ in Expression of Prognosis-related Genes. Clinical Lung Cancer, 2013, 14, 666-673.e2.	1.1	34
166	EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?. Lancet Oncology, The, 2013, 14, 916-917.	5.1	12
167	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 2013, 24, 2206-2223.	0.6	2,805
168	Adjuvant MAGE-A3 Immunotherapy in Resected Non-“Small-Cell Lung Cancer: Phase II Randomized Study Results. Journal of Clinical Oncology, 2013, 31, 2396-2403.	0.8	275
169	Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: The role of Rad51. Breast, 2013, 22, 1178-1183.	0.9	15
170	Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype. Breast, 2013, 22, 425-430.	0.9	1
171	Identification of recurrent <i><sc>FGFR3</sc></i> fusion genes in lung cancer through kinome-“centred <sc>RNA</sc> sequencing. Journal of Pathology, 2013, 230, 270-276.	2.1	113
172	Panitumumab-“FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer. New England Journal of Medicine, 2013, 369, 1023-1034.	13.9	1,971
173	A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines. Breast Journal, 2013, 19, 240-249.	0.4	16
174	Beneath the Blood Brain Barrier: The Challenge of Diagnosis and Management of Central Nervous System Involvement in ALK-Positive Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1465-1466.	0.5	4
175	The role of hormonal factors and endocrine therapy in ovarian cancer. Wspolczesna Onkologia, 2013, 1, 14-19.	0.7	7
176	LETTER TO EDITOR REPLY. Polish Journal of Pathology, 2013, 4, 317-318.	0.1	1
177	Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients. PLoS ONE, 2013, 8, e72219.	1.1	20
178	Primary leiomyosarcoma of the mesentery in two sisters: clinical and molecular characteristics. Polish Journal of Pathology, 2013, 1, 59-63.	0.1	10
179	Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study.. Journal of Clinical Oncology, 2013, 31, 2031-2031.	0.8	4
180	Analysis of <i>KRAS/NRAS</i> and <i>BRAF</i> mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2013, 31, 3511-3511.	0.8	43

#	ARTICLE	IF	CITATIONS
181	Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2013, 31, 3620-3620.	0.8	8
182	A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, TPS8121-TPS8121.	0.8	2
183	Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, LBA445-LBA445.	0.8	4
184	Narodowe strategie zwalczania nowotworów: doświadczenia, struktura, dobre praktyki. Nowotwory, 2013, 63, 368-374.	0.1	4
185	Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, 3575-3575.	0.8	1
186	Time trends in overall survival (OS) gain in advanced non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19144-e19144.	0.8	0
187	Quantitative measurements of p95HER2 (p95) protein expression in tumors from patients with metastatic breast cancer (MBC) treated with trastuzumab: Independent confirmation of the p95 clinical cutoff.. Journal of Clinical Oncology, 2013, 31, 604-604.	0.8	0
188	Prognostic value of microRNAs (miRs) expression in stage I-III lung adenocarcinoma (AC).. Journal of Clinical Oncology, 2013, 31, 11069-11069.	0.8	0
189	Uwarunkowania opinii, w diagnostyce i terapii kobiet chorych na raka piersi w Polsce związane z postawami chorych. Nowotwory, 2013, 63, 286-294.	0.1	2
190	List otwarty Przewodniczącego Zarządu Głównego Polskiego Towarzystwa Onkologicznego. Nowotwory, 2013, 63, 382-382.	0.1	0
191	Correlation Between Quantitative HER2 Protein Expression and Risk for Brain Metastases in HER2 + Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. Oncologist, 2012, 17, 26-35.	1.9	39
192	Prognostic Significance of TOP2A Gene Dosage in HER-2-Negative Breast Cancer. Oncologist, 2012, 17, 1246-1255.	1.9	22
193	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. Clinical Cancer Research, 2012, 18, 4841-4849.	3.2	124
194	Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. Journal of Clinical Oncology, 2012, 30, 709-717.	0.8	110
195	Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 982-992.	0.5	15
196	Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 340-347.	0.5	147
197	Maintenance chemotherapy in advanced non-small-cell lung cancer. Lancet Oncology, The, 2012, 13, 217-218.	5.1	3
198	Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Research, 2012, 14, R119.	2.2	87

#	ARTICLE	IF	CITATIONS
199	Continuous 7-Days-A-Week External Beam Irradiation in Locally Advanced Cervical Cancer: Final Results of the Phase I/II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1256-1261.	0.4	0
200	Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 554-558.	3.4	23
201	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 27-33.	2.2	4
202	Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 807-814.	3.4	25
203	Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. <i>European Journal of Cancer</i> , 2012, 48, 3439-3447.	1.3	37
204	Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer. <i>Pathology and Oncology Research</i> , 2012, 18, 885-894.	0.9	21
205	Randomized Clinical Trials Using New Technologies in Radiation Oncology: Ethical Dilemma for Medicine and Science. <i>Journal of Thoracic Oncology</i> , 2012, 7, 3-4.	0.5	1
206	Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies. <i>Breast</i> , 2012, 21, 89-94.	0.9	12
207	Hypofractionated radiotherapy for early breast cancer: Review of phase III studies. <i>Reports of Practical Oncology and Radiotherapy</i> , 2012, 17, 66-70.	0.3	17
208	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 505-505.	0.8	7
209	Quantitative HER2 levels and steroid receptor expression in primary breast cancers and in matched brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 603-603.	0.8	2
210	Independent validation of prognostic value of 22 micrnas (miRs) in stage I-II squamous cell lung cancer (SqCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10561-10561.	0.8	1
211	Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21099-e21099.	0.8	0
212	Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer. <i>Drugs</i> , 2011, 71, 1385-1396.	4.9	164
213	Cardiovascular effects of systemic cancer treatment. <i>Cancer Treatment Reviews</i> , 2011, 37, 300-311.	3.4	183
214	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2011, 12, 527-539.	5.1	116
215	MicroRNA in lung cancer diagnostics and treatment. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 717, 25-31.	0.4	52
216	Partial breast irradiation techniques in early breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2011, 16, 213-220.	0.3	15

#	ARTICLE	IF	CITATIONS
217	Pattern of care in locally advanced breast cancer: Focus on local therapy. <i>Breast</i> , 2011, 20, 145-150.	0.9	17
218	Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 755-765.	1.1	22
219	Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 97-100.	0.8	34
220	Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5257-5267.	3.2	75
221	Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1905-1911.	0.5	50
222	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 409-418.	1.1	65
223	Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. <i>Clinical Biochemistry</i> , 2010, 43, 891-898.	0.8	10
224	Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non-Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression. <i>Journal of Clinical Oncology</i> , 2010, 28, 2174-2180.	0.8	116
225	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4697-4705.	0.8	1,644
226	Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial. <i>Onkologie</i> , 2009, 32, 1-1.	1.1	13
227	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 284-290.	3.2	134
228	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. <i>Nature Medicine</i> , 2009, 15, 68-74.	15.2	566
229	The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review. <i>European Journal of Cancer</i> , 2009, 45, 2749-2758.	1.3	33
230	Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 2940-2946.	1.3	24
231	Comparison of two techniques of interstitial pulsed dose rate boost brachytherapy in conservative treatment of breast cancer. <i>Journal of Contemporary Brachytherapy</i> , 2009, 1, 33-37.	0.4	3
232	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1980-1986.	0.8	189
233	Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1987-1992.	0.8	314
234	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2008, 14, 4794-4799.	3.2	99



#	ARTICLE	IF	CITATIONS
235	Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2008, 26, 1698-1704.	0.8	215
236	Intergroup Exemestane Study mature analysis: overall survival data. <i>Anti-Cancer Drugs</i> , 2008, 19, S3-S7.	0.7	8
237	Exemestane: an alternative treatment option in early breast cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, S1.	0.7	0
238	Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. <i>Journal of Clinical Oncology</i> , 2007, 25, 5210-5217.	0.8	465
239	The role of radiotherapy in lung cancer: Where is the evidence?. <i>Radiotherapy and Oncology</i> , 2007, 83, 203-213.	0.3	58
240	Gene copy numbers of HER family in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 134, 271-279.	1.2	22
241	Correction of Anemia with Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), in Oncology Patients Receiving Chemotherapy.. <i>Blood</i> , 2007, 110, 3666-3666.	0.6	2
242	Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2006, 7, 719-727.	5.1	1,458
243	Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. <i>Lung Cancer</i> , 2006, 52, 155-163.	0.9	304
244	Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy. <i>Acta Oncologica</i> , 2006, 45, 695-701.	0.8	30
245	Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy.. <i>Blood</i> , 2006, 108, 1290-1290.	0.6	3
246	Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. <i>Journal of Clinical Oncology</i> , 2005, 23, 2831-2839.	0.8	159
247	Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: A randomised phase III study (EORTC 10974/22002, LAMANOMA) – Why did this study fail?. <i>European Journal of Cancer</i> , 2005, 41, 2787-2788.	1.3	12
248	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1081-1092.	13.9	1,694
249	Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. <i>Journal of Clinical Oncology</i> , 2004, 22, 269-276.	0.8	59
250	P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with non-small cell lung carcinoma. <i>Cancer</i> , 2004, 100, 1951-1960.	2.0	20
251	Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: A report on patient compliance and acute toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 814-821.	0.4	55
252	Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation. <i>Cancer Treatment Reviews</i> , 2004, 30, 671-682.	3.4	21



#	ARTICLE	IF	CITATIONS
253	Chemotherapy of Metastatic Breast Cancer: Is more better?. Breast Cancer Research and Treatment, 2003, 81, 37-42.	1.1	2
254	Role of chemotherapy in the multimodality approach of non-small cell lung cancer. Current Problems in Cancer, 2003, 27, 64-68.	1.0	1
255	Modern management of symptoms and quality of life. Current Problems in Cancer, 2003, 27, 69-73.	1.0	3
256	Gemcitabine and anthracyclines in breast cancer. Seminars in Oncology, 2003, 30, 11-14.	0.8	57
257	Chemoradiotherapy of nonsmall cell lung cancer. Expert Review of Anticancer Therapy, 2002, 2, 402-407.	1.1	1
258	A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. Lung Cancer, 2002, 35, 73-79.	0.9	36
259	Combined chemotherapy and radiotherapy in inoperable non-small cell lung cancer. Lung Cancer, 2002, 38, 43-46.	0.9	43
260	Cancer clinical trials in Central and Eastern Europe: historical review. Critical Reviews in Oncology/Hematology, 2002, 42, 157-161.	2.0	6
261	The feasibility study on continuous 7-day-a-week external beam irradiation in locally advanced cervical cancer: a report on acute toxicity. Radiotherapy and Oncology, 2001, 61, 197-202.	0.3	10
262	Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial. Journal of Clinical Oncology, 2001, 19, 1707-1715.	0.8	297
263	Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer. , 2001, 3, 60-71.		4
264	Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Human Mutation, 2000, 15, 480-481.	1.1	33
265	Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. , 2000, 15, 480.		1
266	Does chemotherapy-induced leukopenia predict a response in small-cell lung cancer?. Journal of Cancer Research and Clinical Oncology, 1998, 124, 106-112.	1.2	6
267	Primary cancer of the fallopian tube. Acta Obstetrica Et Gynecologica Scandinavica, 1996, 75, 281-286.	1.3	13